DWTX
Dogwood Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.29
−2.14%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -20.9%
- EBIT
- -62.5%
- EPS
- +51.3%
- Free cash flow
- +4.1%
- Operating cash flow
- +4.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +92.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +65.5%
- Free cash flow
- -77.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026